18F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study
Background: Amyloid positron emission tomography (PET) can measure in-vivo demyelination in patients with multiple sclerosis (MS). However, the value of 18F-labeled amyloid PET tracer, 18F-florbetapir in the longitudinal study for monitoring myelin loss and recovery has not been confirmed. Methods:...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-07-01
|
| Series: | EClinicalMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537021002625 |
| _version_ | 1819150772725612544 |
|---|---|
| author | Min Zhang You Ni Qinming Zhou Lu He Huanyu Meng Yining Gao Xinyun Huang Hongping Meng Peihan Li Meidi Chen Danni Wang Jingyi Hu Qiu Huang Yao Li Fabien Chauveau Biao Li Sheng Chen |
| author_facet | Min Zhang You Ni Qinming Zhou Lu He Huanyu Meng Yining Gao Xinyun Huang Hongping Meng Peihan Li Meidi Chen Danni Wang Jingyi Hu Qiu Huang Yao Li Fabien Chauveau Biao Li Sheng Chen |
| author_sort | Min Zhang |
| collection | DOAJ |
| description | Background: Amyloid positron emission tomography (PET) can measure in-vivo demyelination in patients with multiple sclerosis (MS). However, the value of 18F-labeled amyloid PET tracer, 18F-florbetapir in the longitudinal study for monitoring myelin loss and recovery has not been confirmed. Methods: From March 2019 to September 2020, twenty-three patients with MS and nine healthy controls (HCs) underwent a hybrid PET/MRI at baseline and expanded disability status scale (EDSS) assessment, and eight of 23 patients further underwent follow-up PET/MRI. The distribution volume ratio (DVR) and standard uptake value ratio (SUVR) of 18F-florbetapir in damaged white matter (DWM) and normal-appearance white matter (NAWM) were obtained from dynamic and static PET acquisition. Diffusion tensor imaging-derived parameters were also calculated. Data were expressed as mean ± standard deviation with 99% confidence interval (99%CI). Finding: The mean DVR (1.08 ± 0.12, 99%CI [1.02 ~ 1.14]) but not the mean SUVR of DWM lesions was lower than that of NAWM in patients with MS (1.25 ± 0.10, 99%CI [1.20 ~ 1.31]) and HCs (1.29 ± 0.08, 99%CI [1.23 ~ 1.36]). A trend toward lower mean fractional anisotropy (374.95 ± 45.30 vs. 419.07 ± 4.83) and higher mean radial diffusivity (0.45 ± 0.05 vs. 0.40 ± 0.01) of NAWM in patients with MS than those in HCs was found. DVR decreased in DWM lesions with higher MD (rho = -0.261, 99%CI [-0.362 ~ -0.144]), higher AD (rho = -0.200, 99%CI [-0.318 ~ -0.070]) and higher RD (rho = -0.198, 99%CI [-0.313 ~ -0.075]). Patients’ EDSS scores were reduced (B = 0.04, 99%CI [-0.005 ~ 0.084]) with decreased index of global demyelination in the longitudinal study. Interpretation: Our exploratory study suggests that dynamic 18F-florbetapir PET/MRI may be a very promising tool for quantitatively monitoring myelin loss and recovery in patients with MS. Funding: Shanghai Pujiang Program, Shanghai Municipal Key Clinical Specialty, Shanghai Shuguang Plan Project, Shanghai Health and Family Planning Commission Research Project, Clinical Research Plan of SHDC, French-Chinese program ''Xu Guangqi''. |
| first_indexed | 2024-12-22T14:22:49Z |
| format | Article |
| id | doaj.art-a59b738b0a5842b0876a31a7e99315c9 |
| institution | Directory Open Access Journal |
| issn | 2589-5370 |
| language | English |
| last_indexed | 2024-12-22T14:22:49Z |
| publishDate | 2021-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EClinicalMedicine |
| spelling | doaj.art-a59b738b0a5842b0876a31a7e99315c92022-12-21T18:22:57ZengElsevierEClinicalMedicine2589-53702021-07-013710098218F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal studyMin Zhang0You Ni1Qinming Zhou2Lu He3Huanyu Meng4Yining Gao5Xinyun Huang6Hongping Meng7Peihan Li8Meidi Chen9Danni Wang10Jingyi Hu11Qiu Huang12Yao Li13Fabien Chauveau14Biao Li15Sheng Chen16Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025, ChinaDepartment of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025, ChinaDepartment of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025, ChinaDepartment of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025, ChinaDepartment of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025, ChinaDepartment of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, ChinaSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, ChinaInstitute for Medical Imaging Technology, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, ChinaInstitute for Medical Imaging Technology, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Institute for Medical Imaging Technology, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, ChinaUniv Lyon, Lyon Neuroscience research Center, CNRS UMR5292, INSERM U1028, Univ Lyon 1, Lyon, FranceDepartment of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Corresponding authors.Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025, China; Corresponding authors.Background: Amyloid positron emission tomography (PET) can measure in-vivo demyelination in patients with multiple sclerosis (MS). However, the value of 18F-labeled amyloid PET tracer, 18F-florbetapir in the longitudinal study for monitoring myelin loss and recovery has not been confirmed. Methods: From March 2019 to September 2020, twenty-three patients with MS and nine healthy controls (HCs) underwent a hybrid PET/MRI at baseline and expanded disability status scale (EDSS) assessment, and eight of 23 patients further underwent follow-up PET/MRI. The distribution volume ratio (DVR) and standard uptake value ratio (SUVR) of 18F-florbetapir in damaged white matter (DWM) and normal-appearance white matter (NAWM) were obtained from dynamic and static PET acquisition. Diffusion tensor imaging-derived parameters were also calculated. Data were expressed as mean ± standard deviation with 99% confidence interval (99%CI). Finding: The mean DVR (1.08 ± 0.12, 99%CI [1.02 ~ 1.14]) but not the mean SUVR of DWM lesions was lower than that of NAWM in patients with MS (1.25 ± 0.10, 99%CI [1.20 ~ 1.31]) and HCs (1.29 ± 0.08, 99%CI [1.23 ~ 1.36]). A trend toward lower mean fractional anisotropy (374.95 ± 45.30 vs. 419.07 ± 4.83) and higher mean radial diffusivity (0.45 ± 0.05 vs. 0.40 ± 0.01) of NAWM in patients with MS than those in HCs was found. DVR decreased in DWM lesions with higher MD (rho = -0.261, 99%CI [-0.362 ~ -0.144]), higher AD (rho = -0.200, 99%CI [-0.318 ~ -0.070]) and higher RD (rho = -0.198, 99%CI [-0.313 ~ -0.075]). Patients’ EDSS scores were reduced (B = 0.04, 99%CI [-0.005 ~ 0.084]) with decreased index of global demyelination in the longitudinal study. Interpretation: Our exploratory study suggests that dynamic 18F-florbetapir PET/MRI may be a very promising tool for quantitatively monitoring myelin loss and recovery in patients with MS. Funding: Shanghai Pujiang Program, Shanghai Municipal Key Clinical Specialty, Shanghai Shuguang Plan Project, Shanghai Health and Family Planning Commission Research Project, Clinical Research Plan of SHDC, French-Chinese program ''Xu Guangqi''.http://www.sciencedirect.com/science/article/pii/S258953702100262518F-florbetapirPET/MRIDemyelinationMyelin loss and recoveryMultiple sclerosis |
| spellingShingle | Min Zhang You Ni Qinming Zhou Lu He Huanyu Meng Yining Gao Xinyun Huang Hongping Meng Peihan Li Meidi Chen Danni Wang Jingyi Hu Qiu Huang Yao Li Fabien Chauveau Biao Li Sheng Chen 18F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study EClinicalMedicine 18F-florbetapir PET/MRI Demyelination Myelin loss and recovery Multiple sclerosis |
| title | 18F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study |
| title_full | 18F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study |
| title_fullStr | 18F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study |
| title_full_unstemmed | 18F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study |
| title_short | 18F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study |
| title_sort | 18f florbetapir pet mri for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis a longitudinal study |
| topic | 18F-florbetapir PET/MRI Demyelination Myelin loss and recovery Multiple sclerosis |
| url | http://www.sciencedirect.com/science/article/pii/S2589537021002625 |
| work_keys_str_mv | AT minzhang 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT youni 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT qinmingzhou 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT luhe 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT huanyumeng 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT yininggao 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT xinyunhuang 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT hongpingmeng 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT peihanli 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT meidichen 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT danniwang 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT jingyihu 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT qiuhuang 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT yaoli 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT fabienchauveau 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT biaoli 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy AT shengchen 18fflorbetapirpetmriforquantitativelymonitoringmyelinlossandrecoveryinpatientswithmultiplesclerosisalongitudinalstudy |